Publicaciones científicas
Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging
Hernández-Sierra A (1,2), Rovira J (2), Petit A (3), Moya-Rull D (2), Mazuecos MA (4), Sánchez-Fructuoso AI (5), Errasti P (6), Idoate MÁ (7), Cruzado JM (8), Vidal A(9), Diekmann F (1,2), Oppenheimer F (1,2), Campistol JM (1,2), Revuelta I (1,2).
RESUMEN
Kaposi's sarcoma (KS) is one of the most frequent transplant related tumors. Several pathways are involved; however, the impact of the molecular phenotype associated to the tumor stage and the behavior-depending resultant therapy are still unknown.
The aim of our study was to analyze the role of HHV-8 and mTOR pathway in tumor stages of skin KS after renal transplantation. Twelve renal transplant recipients with cutaneous KS from five transplant centers (1980-2007) under reduction of immunosuppression or conversion to mTOR inhibitor were included.
The expression of HHV-8, PTEN, TGFβ, VEGF, phospho-mTOR and phospho-P70S6K in tumoral tissue was analyzed. KS lesions were classified as patch, plaque and nodule state. HHV-8 infection was found in all tissue samples. KS lesions showed high activation of VEGF, p-mTOR and p-P70S6K, low PTEN, and null TGFβ expression.
The only pathway activated in a staging dependent manner was mTOR with higher p-mTOR and p-P70S6K expression in nodule versus patch stage. KS lesions disappeared after 5.24 months in all converted patients without any recurrence in 14.05 years of mean follow-up. The activation of mTOR pathway according to KS stages supports the rational of the mTOR inhibitor in posttransplant Kaposi.
CITA DEL ARTÍCULO Transpl Int. 2016 May 21. doi: 10.1111/tri.12800